A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1

Kang,Jiankang; Zhong,Yanping; Tian,Wei; Li,Junying; Li,Xinxiao; Zhai,Lina; Hou,Huaxin; Li,Danrong

doi:10.3892/ijo.2021.5199

A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1

Authors:
- Jiankang Kang
- Yanping Zhong
- Wei Tian
- Junying Li
- Xinxiao Li
- Lina Zhai
- Huaxin Hou
- Danrong Li
View Affiliations

Affiliations: Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, College of Pharmacy, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: March 9, 2021 https://doi.org/10.3892/ijo.2021.5199
Article Number: 19

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At present, effective therapeutic drugs for triple‑negative breast cancer (TNBC) are lacking due to the absence of identified or available targets. Therefore, the present study aimed to identify key molecular targets and a specific targeted therapeutic drug to aid with the development of novel therapeutic strategies for TNBC. Based on the high expression of EGFR and Rac1 in TNBC and inspired by a novel antitumor strategy termed combi‑targeting, novel anthraquinone‑quinazoline hybrid 7B was synthesized to simultaneously target EGFR and Rac1. It was hypothesized that hybrid 7B may possess enhanced potency compared with its parent compounds. Breast cancer cell viability was detected by performing MTT assays. Flow cytometry was conducted to detect the effects of hybrid 7B on the cell cycle, apoptosis and the mitochondrial outer membrane potential. Ultrastructural alterations were observed by transmission electron microscopy. Cell invasion and migration were assessed by performing Transwell and wound‑healing assays, respectively. The expression levels of epithelial‑mesenchymal transition (EMT) markers and metastasis‑related proteins were detected by western blotting. Compared with Rhein and gefitinib, hybrid 7B displayed superior antiproliferative activity in MDA‑MB‑231 cells with an IC₅₀ value of 2.31 µM, which was 14‑fold higher compared with the EGFR tyrosine kinase inhibitor gefitinib. Further experiments demonstrated that hybrid 7B significantly reduced the mitochondrial membrane potential, enhanced MDA‑MB‑231 cell apoptosis and induced cell cycle arrest at the G₂/M phase compared with the control group. Typical morphological alterations of apoptotic cells were observed in hybrid 7B‑treated MDA‑MB‑231 and MCF‑7 cells. Compared with the control group, hybrid 7B significantly inhibited MDA‑MB‑231 cell invasion and migration by downregulating Rac1, EGFR, matrix metalloproteinases, snail family transcriptional repressor 1, Vimentin and β‑catenin protein expression levels, and upregulating E‑cadherin protein expression levels. The present study demonstrated that hybrid 7B inhibited TNBC cell migration and invasion by reversing EMT and targeting EGFR and Rac1; therefore, hybrid 7B may serve as a promising therapeutic agent for TNBC.

View Figures

View References

1	Yin L, Duan JJ, Bian XW and Yu SC: Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
2	McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM, Polychronis A, Coombes RC and Lam EW: Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 8:582–591. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
4	Matsuda N, Lim B, Wang X and Ueno NT: Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opin Investig Drugs. 26:463–479. 2017. View Article : Google Scholar : PubMed/NCBI
5	Peng B, He R, Xu Q, Yang Y, Hu Q, Hou H, Liu X and Li J: Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway. Pharmacol Res. 142:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
6	Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, et al: Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treat Rev. 62:1–8. 2018. View Article : Google Scholar
7	Payapilly A and Malliri A: Compartmentalisation of RAC1 signalling. Curr Opin Cell Biol. 54:50–56. 2018. View Article : Google Scholar : PubMed/NCBI
8	Su Z, Li Z, Wang C, Tian W, Lan F, Liang D, Li J, Li D and Hou H: A novel Rhein derivative: Activation of Rac1/NADPH pathway enhances sensitivity of nasopharyngeal carcinoma cells to radiotherapy. Cell Signal. 54:35–45. 2019. View Article : Google Scholar
9	Zhou G, Peng F, Zhong Y, Chen Y, Tang M and Li D: Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells. Int J Oncol. 50:933–941. 2017. View Article : Google Scholar : PubMed/NCBI
10	Roskoski R Jr: ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacol Res. 87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI
11	Liang D, Su Z, Tian W, Li J, Li Z, Wang C, Li D and Hou H: Synthesis and screening of novel anthraquinone-quinazoline multitarget hybrids as promising anticancer candidates. Future Med Chem. 12:111–126. 2020. View Article : Google Scholar
12	Klöditz K and Fadeel B: Three cell deaths and a funeral: Macrophage clearance of cells undergoing distinct modes of cell death. Cell Death Discov. 5:652019. View Article : Google Scholar : PubMed/NCBI
13	Daddam JR, Dowlathabad MR, Panthangi S and Jasti P: Molecular docking and P-glycoprotein inhibitory activity of flavonoids. Interdiscip Sci. 6:167–175. 2014. View Article : Google Scholar : PubMed/NCBI
14	Stivarou T and Patsavoudi E: Extracellular molecules involved in cancer cell invasion. Cancers (Basel). 7:238–265. 2015. View Article : Google Scholar
15	Williams CB, Soloff AC, Ethier SP and Yeh ES: Perspectives on epidermal growth factor receptor regulation in triple-negative breast cancer: Ligand-mediated mechanisms of receptor regulation and potential for clinical targeting. Adv Cancer Res. 127:253–281. 2015. View Article : Google Scholar : PubMed/NCBI
16	Sporikova Z, Koudelakova V, Trojanec R and Hajduch M: Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 18:e841–e850. 2018. View Article : Google Scholar : PubMed/NCBI
17	Al-Mahmood S, Sapiezynski J, Garbuzenko OB and Minko T: Metastatic and triple-negative breast cancer: Challenges and treatment options. Drug Deliv Transl Res. 8:1483–1507. 2018. View Article : Google Scholar : PubMed/NCBI
18	Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, et al: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 23:5323–5333. 2005. View Article : Google Scholar : PubMed/NCBI
19	El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F and Aubel C: Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 10:63672020. View Article : Google Scholar : PubMed/NCBI
20	Bid HK, Roberts RD, Manchanda PK and Houghton PJ: RAC1: An emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther. 12:1925–1934. 2013. View Article : Google Scholar : PubMed/NCBI
21	Shi Y, Su C, Cui W, Li H, Liu L, Feng B, Liu M, Su R and Zhao L: Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells. J Nanobiotechnology. 12:432014. View Article : Google Scholar : PubMed/NCBI
22	Kaneto N, Yokoyama S, Hayakawa Y, Kato S, Sakurai H and Saiki I: RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer. Cancer Sci. 105:788–794. 2014. View Article : Google Scholar : PubMed/NCBI
23	Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ and Zinn KR: Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biol Ther. 15:1053–1060. 2014. View Article : Google Scholar : PubMed/NCBI
24	Chen Y, Chen X, Ding X and Wang Y: Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh-7 cells by regulating the ERK-VEGF/MMP9 signaling pathway. Mol Med Rep. 20:3317–3325. 2019.PubMed/NCBI
25	Kim TI, Kim H, Lee DJ, Choi SI, Kang SW and Kim EK: Altered mitochondrial function in type 2 granular corneal dystrophy. Am J Pathol. 179:684–692. 2011. View Article : Google Scholar : PubMed/NCBI
26	Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, et al: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 8:157732017. View Article : Google Scholar : PubMed/NCBI
27	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kim S and Lee JW: Membrane proteins involved in epithelial-mesenchymal transition and tumor invasion: Studies on TMPRSS4 and TM4SF5. Genomics Inform. 12:12–20. 2014. View Article : Google Scholar : PubMed/NCBI
29	Jang MH, Kim HJ, Kim EJ, Chung YR and Park SY: Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol. 46:1267–1274. 2015. View Article : Google Scholar : PubMed/NCBI
30	Tien Y, Tsai CL, Hou WH, Chiang Y, Hsu FM, Tsai YC and Cheng JC: Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells. Radiat Oncol. 15:582020. View Article : Google Scholar : PubMed/NCBI
31	Yoon C, Cho SJ, Chang KK, Park DJ, Ryeom SW and Yoon SS: Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res. 15:1106–1116. 2017. View Article : Google Scholar : PubMed/NCBI
32	Santibanez JF, Obradović H, Kukolj T and Krstić J: Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Dev Dyn. 247:382–395. 2018. View Article : Google Scholar
33	Zhuge Y and Xu J: Rac1 mediates type I collagen-dependent MMP-2 activation. Role in cell invasion across collagen barrier. J Biol Chem. 276:16248–16256. 2001. View Article : Google Scholar : PubMed/NCBI
34	Binker MG, Binker-Cosen AA, Richards D, Oliver B and Cosen-Binker LI: LPS-stimulated MUC5AC production involves Rac1-dependent MMP-9 secretion and activation in NCI-H292 cells. Biochem Biophys Res Commun. 386:124–129. 2009. View Article : Google Scholar : PubMed/NCBI
35	Cox G, Jones JL and O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 6:2349–2355. 2000.PubMed/NCBI
36	Elkhalifa D, Siddique AB, Qusa M, Cyprian FS, El Sayed K, Alali F, Al Moustafa AE and Khalil A: Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer. Eur J Med Chem. 187:1119542020. View Article : Google Scholar
37	Martin JL, de Silva HC, Lin MZ, Scott CD and Baxter RC: Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther. 13:316–328. 2014. View Article : Google Scholar